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AbstrACt
Objective To identify and compare emollient formularies 
across all clinical commissioning groups (CCGs) and local 
health boards (LHBs) in England and Wales.
Design Formularies were retrieved via CCG/LHB websites 
or Google search (October 2016–February 2017). Data 
on structure and content were extracted, and descriptive 
analyses were undertaken.
setting 209 English CCGs and 7 Welsh LHBs.
Main outcome measures Number and structure of 
formularies; number, type and name of emollients and 
bath additive recommendedandnot recommended; and 
any rationale given.
results 102formularies were identified, which named 
109 emollients and 24 bath additives. Most were 
structured in an ‘order of preference’ (63%) and/or 
formulation (51%) format. Creams and ointments were the 
most commonly recommended types of emollients, and 
three ointments were the most commonly recommended 
specific emollients (71%–79% of formularies). However, 
there was poor consensus over which emollient should be 
used first line and 4 out of 10 of the most recommended 
lotions and creams contained antimicrobials or urea. 
Patient preference (60%) and/or cost (58%) were the 
most common reasons given for the recommendations. 
Of the 82% of formularies that recommend the use of 
bath additives, 75% did not give any reasons for their 
recommendation.
Conclusions Emollient formularies in England and Wales 
vary widely in their structure, recommendations and 
rationale. The reasons for such inconsistencies are unclear, 
risk confusion and make for inequitable regional variation. 
There is poor justification for multiple different, conflicting 
formularies.
IntrODuCtIOn 
The annual spend on emollients in England 
alone in 2015/2016 was £116.2 million.1 
Despite their accepted value in dry skin condi-
tions such as atopic eczema, there are multiple 
products that come in different formulations 
(ointments, gels, creams, lotions, sprays and 
bath additives) and a weak evidence base to 
guide their use.2–4 
Most prescribing of emollients happens 
in primary care and clinical commissioning 
groups (CCGs) in England and local health 
boards (LHBs) in Wales, who have the respon-
sibility for the provision of National Health 
Service (NHS) care in their locality, maintain 
local prescribing formularies. National Insti-
tute for Health and Care Excellence (NICE) 
guidelines states that such information 
should be published ‘… in a clear, simple and 
transparent way, so that patients, the public 
and stakeholders can easily understand it’.5
The need for multiple formularies is ques-
tionable, although the number, type and 
content of recommendations made has never 
been examined. Therefore, we sought to iden-
tify and compare the structure and content 
of emollient formularies across England and 




First, CCGs in England and LHBs in Wales 
were identified using the NHS choices (www. 
nhs. uk), NHS England (www. england. nhs. 
uk, as listed in October 2016) and NHS Wales 
websites (www. wales. nhs. uk, February 2017). 
All available formularies were identified by 
systematically searching each CCG/LHB 
strengths and limitations of this study
 ► This is the first study to compare in a systematic 
way all of the emollient formularies in England and 
Wales.
 ► Due to the labour-intensive nature of data extraction 
and constant change in clinical commissioning 
group/local health board service configuration and 
formularies, it is impossible to have an up-to-date 
national picture at any one point in time.
 ► Very few formularies referred to specific diseases or 
populations (age and ethnicity), so we were unable 
report recommendations at this level.
 ► Ambiguity in many of the formularies, differences 
in researcher interpretation and transcription errors 
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website or undertaking Google searches using relevant 
keywords.
JPC and GB extracted data from each formulary into 
‘leave on’ and bath additive Excel spreadsheets templates, 
respectively. These templates were initially piloted and 
developed with a sample of formularies. To ensure consis-
tency of data extraction, a codebook detailing the various 
coding options was developed alongside. An indepen-
dent check of 10 formularies identified discrepancies 
in 4.7% (57/1220) of ‘leave on’ emollient (PAQ) and 
9.8% (44/448) of bath additive (JPC) data points. Where 
disagreements arose, the two data extractors discussed 
and agreed what should be recorded; most stemmed 
from differing interpretations of vague and/or inconsis-
tent formularies rather than random errors.
Analysis
Data were then imported and analysed descriptively 
using STATA (V.14). All percentages were rounded to the 
nearest whole number unless stated otherwise.
Patient involvement
‘Which emollient is the most effective and safe in treating 
eczema?’ was identified as a priority for research in a 
patient and clinician-led prioritisation exercise published 
in 2013.6 Public and patient involvement in subsequent 
eczema research led by MJR has reinforced the impor-
tance of understanding the variation in emollient 
prescribing and recommendations made by different 
doctors and specialist nurses better.7–9 However, patients 
were not involved in the design of the study or the inter-
pretation of the findings.
results
Eighty-nine per cent (185/209) of CCGs had an emollient 
formulary and all seven LHBs had an emollient formulary 
(figure 1). Seventy-one per cent (131/185) CCGs shared 
an emollient formulary with at least one other CCG, but 
all seven LHBs had their own individual emollient formu-
lary. Some CCGs (24/209) withheld formularies for 
internal use only or did not respond, even after direct 
correspondence, meaning data could only be collected 
from 89% of CCGs. Therefore, overall 102 formularies 
were examined.
The structure of formularies varied, but for emol-
lients, most (63%, 64/102) adopted a ‘rank’ (traffic light, 
medal or number) structure, with by formulation (51%, 
52/102) being next most common, followed by basic 
(alphabetical) list (47%, 48/102) and by skin dryness 
(10%, 10/102) (categories not mutually exclusive). Thir-
ty-four per cent (35/102) of formularies gave the specific 
costs for each emollient.
emollients
Over 109 different emollients were named, with 93 of 
these recommended by at least one formulary. Almost 
every formulary recommended at least one cream (99%) 
or ointment (98%) (see table 1). Most formularies also 
recommended at least one lotion or gel (both 85%), 
but only 29% recommended a spray. No formularies 
censured the use of creams, lotions, ointments or gels. 
However, 9% of formularies recommended against sprays 
and most formularies (62%) made no mention of them. 
‘Other’ types of emollients were most commonly (58%) 
not recommend by formularies. This category contained 
more unusual products such as food-based oils and balms 
(online supplementary table S1).
Cream and ointments were the most commonly recom-
mended types of emollients (table 2). Of the specifically 
recommended and named emollients, three of the ‘top 
five’ are ointments (table 2). However, between 2% and 
9% of formularies specifically did not recommend one 
or more of these products. When ranked by emollient 
type (lotion, cream, gel and ointment), three products 
that contain urea or antimicrobials (Dermol 500 Lotion, 
Dermol Cream and Balneum plus Cream) appear in 
the ‘top five’ (online supplementary table S2). Among 
the 64 formularies that specified an order of preference 
for recommended emollients, generic emulsifying oint-
ment was the most popular first-line emollient, followed 
by three ‘Zero’ products and white soft/liquid paraffin 
50/50 (online supplementary table S3). Aqueous cream 
was the most common emollient not recommended 
(45% of formularies, table 2), although again there 
was disagreement between formularies, with up to 16% 
Figure 1 Flow chart of the clinical commissioning groups 
(CCGs)/local health boards (LHBs) in England/Wales and 
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recommending one or more of the top five not recom-
mended emollients.
The most common reasons given for the recommen-
dations made were patient preference (60%, 61/102) 
and/or product cost (58%, 59/102). Forty-two per cent 
(43/102) of formularies gave other reasons, the most 
common being ‘the greasier the emollient, the better 
the effect’. Other rationale given for not recommending 
emollients included concerns over food-based ingredi-
ents and the ability of active ingredients to penetrate the 
skin. No rationale was given in 28% (29/102).
bath additives
Of the 82% (84/102) of formularies that recommended 
the use of bath additives, 75% (64/84) did not give any 
rationale. Six formularies noted that evidence to support 
their use was lacking, eight recommended their use only 
in specific circumstances and six cited ‘possible benefit 
for some patients’.
There was no mention of bath additives in 7% (7/102) of 
formularies and 11% (11/102) did not recommend their 
routine use. Four per cent (4/102) stated that patients 
should buy their own. The rationale for not prescribing 
bath emollients was variable, the most common (non-ex-
clusive) reasons cited were: lack of evidence (5/11), 
concerns about safety (4/11), the potential to undertreat 
eczema by distracting from leave-on emollient use (3/11) 
and cost (1/11). Three formularies did not give a reason.
Most formularies (92%, 77/84) presented their recom-
mendations as individually named bath additives. A small 
number of formularies (8%, 7/84) also suggested that 
any emollient (except for ‘50:50’) could be used in the 
bath instead of a specific bath additive. Regarding the use 
of bath additives with antimicrobials, they were recom-
mended in 74% (62/84) of formularies, not mentioned 
in 25% (21/84), and one advised against their use ever. 
Of those recommending their use, 34% (21/62) speci-
fied ‘only in the presence of infection’.
Overall, 19 regular and five antimicrobial containing 
bath additives were named (see table 3). The five most 
commonly recommended bath emollients were Oilatum, 
Hydromol, Dermol 600, Oilatum plus and Balneum plus. 
Some formularies restricted use of specific bath additives; 
Table 1 Formularies’ recommendations by type of emollient (n=102)
Formulation
Recommended Not recommended
Neither recommended nor not 
recommended
n % n % n %
Lotion 87 85 0 0 15 15
Cream 101 99 0 0 1 1
Gel 87 85 0 0 15 15
Ointment 100 98 0 0 2 2
Spray 30 29 9 9 63 62
Other 43 42 59 58 0 0
Table 2 Top five emollients most commonly recommended and not recommended by formularies (all types) (n=102)
Name of emollient
Number (%) of formularies
Recommending Not recommending
n % n %
Top five recommended
  White Soft/Liquid Paraffin 50/50 81 79 2 2
  Emulsifying Ointment BP 80 78 2 2
  Hydromol ointment 72 71 6 6
  Dermol 500 Lotion 71 70 9 9
  Cetraben Cream 70 69 6 6
Top five not recommended
  Aqueous Cream 11 11 46 45
  E45 itch relief 10 10 22 22
  Ultrabase Cream 16 16 20 20
  Nutraplus Cream 14 14 19 19
  Dermamist Spray 12 12 18 18
  Lipobase 3 3 18 18
 o
n
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for example, Aveeno was often only recommended if 
paraffin intolerant or following no response to other bath 
emollients.
DIsCussIOn
We found that most CCGs and LHBs (192/216) had 
a formulary, with 102 unique emollient formularies 
between them. Of the 109 different emollients named, 
creams and ointments were the most commonly recom-
mended types, and three ointments (White Soft/Liquid 
Paraffin 50/50, Emulsifying Ointment and Hydromol 
Ointment) were the most frequently specified products. 
However, there was poor consensus over which emollient 
should be used first line, and 4 out of 10 of the most 
recommended lotions and cream contain antimicrobials 
or urea. Patient preference (60%) and/or cost (58%) 
were the most common reasons given for the recommen-
dations. However, cost recommendations were on a ‘price 
per gram or millilitre’ basis, rather than proper cost-effec-
tiveness evidence. Eleven per cent of formularies did not 
recommend the use of bath additives, while the 82% that 
did named 24 different bath additives and most (75%) 
did not give any reasons for their recommendation.
This is the first study to compare all emollient formu-
laries in England and Wales. Formularies were identified, 
and data were extracted in a systematic way. Ambiguity 
in many of the formularies, differences in interpretation 
and transcription errors may mean inaccuracies were 
introduced during this process. In the time between 
collecting and reporting the data, two further CCGs have 
merged (new total 207), and a rapid review of the emol-
lient formularies in November 2017 identified that 50% 
have been updated. However, most changes appear to be 
minor, and the key findings of the number of formularies 
and similarities/differences between the different formu-
laries hold true. Because of the labour-intensive nature 
of data extraction, the constant change in NHS service 
configuration, and CCGs/LHBs independently main-
taining >100 formularies, it is impossible to have an up-to-
date national picture at any one point in time. Very few 
formularies referred to specific diseases or populations 
(age, ethnicity), so we were unable report recommenda-
tions at this level.
One significant factor contributing to the lack of agree-
ment between the formularies is the weak evidence base. 
Several recent systematic reviews have all concluded that 
good quality research comparing the effectiveness or 
acceptability of emollients is very limited.2–4 Likewise, 
there is an absence of evidence to demonstrate the clin-
ical and cost-effectiveness of bath additives.3 The greatest 
consensus is around recommendations for ointments, 
one appeal being their low cost, although current NICE 
guidance on atopic eczema in children (from 2007) notes 
that they are often less acceptable and are therefore ‘not 
usually suitable as a first-line treatment’.10 The predomi-
nance of emollients that contain urea or antimicrobials 
is surprising: these products are usually second-line treat-
ments, generally cost more than standard emollients 
and are more likely to irritate skin.1 11 It is encouraging 
to see 45% of formularies actively not recommending 
aqueous cream, probably reflecting the 2013 Medicines 
and Healthcare products Regulatory Agency (MHRA) 
safety report on adverse skin reactions in children with 
eczema.12 There is a disparity between formulary recom-
mendations and recent NHS community dispensing data 
(for children and adults)13 14 where the top five dispensed 
emollients were Cetraben Cream, Doublebase gel, 
Diprobase cream, Aveeno cream and Dermol 500 Lotion. 
There may be many reasons for this observation, beyond 
the scope of this paper, but which may include: a time 
lag between formulary implementation and prescribing 
patterns changing; prescriber lack of familiarity with 
formulary recommendations; and/or strong clinician or 
patient preference for non-recommended emollients.
We know that much emollient prescribing is done on a 
‘trial and error’ basis,15 16 but the extent to which all these 
Table 3 Regular and antimicrobial containing bath 




n % n %
Regular bath emollients
  Oilatum 51 61 14 17
  Hydromol 43 51 10 12
  Balneum plus 32 38 9 11
  Balneum 30 36 17 20
  Aveeno 24 29 20 24
  Zeroneum 24 29 20 24
  Dermalo 22 26 20 24
  Zerolatum 20 24 21 25
  Double base 19 23 12 14
  Cetraben 18 21 16 19
  QV bath oil 15 18 20 24
  LPL 63.4 13 15 10 12
  E45 13 15 21 25
  Aqueous cream BP 11 13 9 11
  Diprobath 10 12 18 21
  Oilatum Junior 8 10 9 11
  Zerolatum plus 4 5 16 19
  ZeroAQS 2 2 7 8
  Zerozole 1 1 18 21
Bath emollients containing antimicrobial agent
  Dermol 600 41 49 8 10
  Oilatum plus 34 40 11 13
  Emulsiderm 22 26 18 21
  Dermol 14 17 14 17
  Dermol 500 4 5 7 8
 o
n
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different formularies help reduce (or indeed contribute) 
to this problem is unclear. While local formularies can 
reflect the needs of the population served, the justifica-
tion in the case of emollients/bath additives is weak (and 
indeed local factors contributing to decision making 
not specified in any of the formularies). Furthermore, 
we cannot understand why the formularies of 24 CCGs 
are not publicly available. In addition to the time and 
cost of different medicine management teams and area 
prescribing committees developing individual emollient 
formularies, differences between them serves to cause 
confusion to prescribers and patients, especially when 
they move between areas. This combined with the discrep-
ancy between emollient dispensing data and formulary 
recommendations suggests the purpose of emollient 
formularies should be rethought and/or communicated 
more effectively.
While the ‘correct’ emollient is the ‘one that the 
child will use’10 is a pragmatic approach to emollient 
prescribing, it is not one that is supported by formulary 
recommendations that have a weak evidence base. Future 
research should further explore the disparity between 
recommended and observed prescribing of emollients, 
including changes over time in formulary recommenda-
tions and prescribing patterns. The results of ongoing 
pragmatic trials such as Best Emollient for Eczema 
(comparing different emollient types, https:// doi. org/ 
10. 1186/ ISRCTN84540529) and Bath Additives for the 
Treatment of Childhood Eczema (bath additives in addi-
tion to usual care)17 will provide clinical and cost-effec-
tiveness data that will inform, and hopefully simplify, 
formulary recommendations to the benefit of patients 
and clinicians.
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